For many different stakeholders in Switzerland (including policy, health care professionals, infected, other vulnerable population groups) it is crucial that current and future policy decisions on how to minimize the disease and societal burden of SARS-COV-2 are informed by solid data. This in turn requires knowledge of the nation-wide prevalence of SARS-CoV-2 infection at the level of the population, in different geographical areas and of specific age groups. This knowledge will also help prepare future outbreak responses and is also important to inform future vaccination strategies. In a number of Cantons, studies on the seroprevalence of SARS-CoV-2 antibodies and the extent and duration of immunity are planned or have already started. The interest for such epidemiological studies comes from both Cantonal authorities and scientists who want to learn about the seroprevalence of SARS-CoV-2 antibodies, both in the general population (across age ranges) and in specific groups of persons (e.g. nursing home residents, working in specific sectors of economy, from citizens, etc.).
The scientists of the Swiss School of Public Health (SSPH+) have agreed to coordinate their effort in order to make their data as comparable as possible, to create synergies and reduce redundancies. The goal is to make the studies informative for policy makers on the national and Cantonal level while fully respecting the autonomy of the Cantons and scientists involved (https://www.corona-immunitas.ch/). The main aim of this study is to determine the extent and nature of infection with SARS-CoV-2 in the Canton of Zurich and to contribute to consistent estimates in the Swiss population. The overall objectives addressed nation-wide are:
Additional objectives specifically addressed by the Canton of Zurich are:
The study details are published here: Corona Immunitas